Nantahala Capital Management SC 13D Evoke Pharma / Nantahala Capital Management ownership change

Exhibit 99.1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the Common Stock, par value $0.001 per share, of Evoke Pharma, Inc., and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13D.

Date: September 20, 2024

NANTAHALA CAPITAL MANAGEMENT, LLC
By:	/s/ Taki Vasilakis
	Taki Vasilakis
	Chief Compliance Officer
/s/ Wilmot B. Harkey
Wilmot B. Harkey
/s/ Daniel Mack
Daniel Mack